Mga Batayang Estadistika
| LEI | 529900C439Y0Z6RPYG51 |
| CIK | 1369868 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to China Biologic Products Holdings Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| May 12, 2023 |
EXHIBIT 99.2 Specific parts of this Exhibit have been redacted because confidential treatment for those parts has been requested. The redacted materials have been separately provided to the Securities and Exchange Commission, and the redacted parts have been marked at the appropriate places with three asterisks [***] J.P.Morgan On Demand Credit Facility Agreement The BORROWER has requested and the |
|
| May 12, 2023 |
CN:CBPO / China Biologic Products Holdings Inc / Parfield International Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 10)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Na |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as |
|
| April 22, 2021 |
China Biologic Products Holdings, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital Advisors, Ltd. Suite 5B 201 2nd Floor, One Nexus Way PO Box 2587, KY1 |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 17)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Qu |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 China Biologic Products Holdings, Inc. (Name of issuer) Ordinary Shares, par value US$0.0001 per share (Title of |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Nam |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 9) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Name of the Issuer) China Biologic Products Holdings, Inc. CBPO Holdings Limited CBPO Group Limited Beachhead Holdings Limited Double Double Holdings Limited Point |
|
| April 21, 2021 |
As filed with the Securities and Exchange Commission on April 21, 2021 Registration No. |
|
| April 21, 2021 |
EXHIBIT 1 The name, present principal occupation and business address of each director and executive officer of the Reporting Persons is set forth below. |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Jason Norman Lee Managing Director , Legal & Regulatory Temasek International Pte. Ltd. 60B Orchard Road #0 |
|
| April 21, 2021 |
S-8 POS 1 tm2113652d2s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on April 21, 2021 Registration No. 333-151263 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charte |
|
| April 20, 2021 |
China Biologic Announces Completion of Going Private Transaction Exhibit 99.1 China Biologic Announces Completion of Going Private Transaction BEIJING, China ?April 20, 2021 ? China Biologic Products Holdings, Inc. (NASDAQ: CBPO, ?China Biologic? or the ?Company?), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the ?Merger?) with CBPO Group Limited (?Merger Sub?), a wholly owned subsidia |
|
| April 20, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang |
|
| March 29, 2021 |
China Biologic Fourth Quarter and Fiscal Year 2020 Financial Results Exhibit 99.2 China Biologic Fourth Quarter and Fiscal Year 2020 Financial Results Fourth Quarter 2020 Financial Performance Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms, or 3.2% in RMB terms, to $112.1 million from $102.2 million in the same quarter of 2019. Total sales for plasma products increased by 3.0% in USD terms, or decreased by 3.2% in RMB terms, to $93.9 milli |
|
| March 29, 2021 |
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020 Exhibit 99.1 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020 BEIJING, China ? March 29, 2021 ? China Biologic Products Holdings, Inc. (NASDAQ: CBPO, ?China Biologic? or the ?Company?), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2 |
|
| March 29, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang |
|
| March 1, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang |
|
| March 1, 2021 |
China Biologic Announces Shareholders’ Approval of Merger Agreement Exhibit 99.1 China Biologic Announces Shareholders? Approval of Merger Agreement BEIJING, China ?March 1, 2021 ? China Biologic Products Holdings, Inc. (NASDAQ: CBPO, ?China Biologic? or the ?Company?), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, at an extraordinary general meeting (the ?EGM?) held today, the Company?s shareholders voted in fav |
|
| January 25, 2021 |
SC 13E3/A 1 tm214023-1sc13e3a.htm SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 8) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Name of the Issuer) China Biologic Products Holdings, Inc. CBPO Holdings Limited CBPO Group Limited Beachhead Holdings |
|
| January 25, 2021 |
Proxy Statement of the Company dated January 25, 2021. Exhibit (a)-(1) PROXY STATEMENT OF THE COMPANY January 25, 2021 Shareholders of China Biologic Products Holdings, Inc. |
|
| January 25, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm214032d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong I |
|
| January 25, 2021 |
China Biologic Announces Extraordinary General Meeting of Shareholders Exhibit 99.1 China Biologic Announces Extraordinary General Meeting of Shareholders BEIJING, China –January 25, 2021 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”) to be held on March |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Ching Nar Cindy Chan 3201, 32/F One Pacific Place 88 Queensway Hong Kong Tel: +852 3798 8628 (Name, Address and Telephone Number of Person Authorized to Recei |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Nam |
|
| January 15, 2021 |
Exhibit 1 CUSIP No. G21515104 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all additional amendments thereto) with respect to the ordinary shares of China Biologic Products Holdings, Inc. and further agree that this joi |
|
| January 15, 2021 |
Equity Commitment Letter, dated November 19, 2020, issued and delivered by CCF III. Exhibit 6 EXECUTION VERSION EQUITY COMMITMENT LETTER November 19, 2020 Biomedical Treasure Limited PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands Ladies and Gentlemen: This letter agreement sets forth the commitment of CPEChina Fund III, L. |
|
| January 14, 2021 |
Preliminary Proxy Statement of the Company dated ________. Exhibit (a)-(1) PROXY STATEMENT OF THE COMPANY Shareholders of China Biologic Products Holdings, Inc. |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 7) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Name of the Issuer) China Biologic Products Holdings, Inc. CBPO Holdings Limited CBPO Group Limited Beachhead Holdings Limited Double Double Holdings Limited Point |
|
| January 8, 2021 |
SC 13D/A 1 tm212160d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 China Biologic Products Holdings, Inc. (Name of issuer) Ordinary Shares |
|
| January 8, 2021 |
Shareholders’ Agreement in respect of Biomediacal Treasure Limited Exhibit 99.25 SHAREHOLDERS’ AGREEMENT by and among Mr. joseph chow CTB Investment Limited tb friday holdings limited and Biomedical Treasure Limited Dated as of October 26, 2020 -i- TABLE OF CONTENTS Page ARTICLE I DEFINITION 2 1.1 Definitions 2 1.2 Interpretation 5 ARTICLE II CORPORATE PURPOSE AND CORPORATE GOVERNANCE 6 2.1 Purpose of the Company 6 2.2 Voting Rights 6 2.3 Corporate Actions 6 2.4 |
|
| January 8, 2021 |
Joint Filing Agreement dated January 8, 2021 by the Reporting Persons. EX-99.24 2 tm212160d1ex99-24.htm EXHIBIT 99.24 Exhibit 99.24 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (includin |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong +86 10 8478 |
|
| January 7, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm211983d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong I |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Nam |
|
| December 31, 2020 |
SC 13D/A 1 tm2039674d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Level 54, Hopewell Centre 1 |
|
| December 31, 2020 |
EX-99.23 2 tm2039678d1ex99-23.htm EXHIBIT 99.23 Exhibit 99.23 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (includi |
|
| December 31, 2020 |
SC 13D/A 1 tm2039598d1sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Mana |
|
| December 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong |
|
| December 31, 2020 |
SC 13D/A 1 tm2039678d1sc13da.htm SCHEDULE 13D/A AMENDMENT NO. 3 TO SCHEDULE 13D CUSIP No. G21515104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 China Biolog |
|
| December 18, 2020 |
Exhibit (c)-(2) China Biologic Products Holdings, Inc. Fairness Analysis Presented to the Special Committee of Independent Directors November 19 , 20 20 The information contained herein is of a confidential nature and is intended for the use of the persons or firm to whom it is fu rnished by us. Reproduction, publication, or dissemination of any portion hereof may not be made without prior approva |
|
| December 18, 2020 |
SC 13E3/A 1 tm2038517d1sc13e3a.htm SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 6) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Name of the Issuer) China Biologic Products Holdings, Inc. CBPO Holdings Limited CBPO Group Limited Beachhead Holdings |
|
| December 18, 2020 |
Exhibit (a)-(1) PROXY STATEMENT OF THE COMPANY Shareholders of China Biologic Products Holdings, Inc. |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 5) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934 China Biologic Products Holdings, Inc. (Name of the Issuer) Beachhead Holdings Limited Double Double Holdings Limited Point Forward Holdings Limited Centurium Capital Partners 2018, L.P. Centurium Capita |
|
| November 25, 2020 |
Exhibit (b)-(3) Specific parts of this Exhibit have been redacted because confidential treatment for those parts has been requested. |
|
| November 24, 2020 |
China Biologic Reports Financial Results for the Third Quarter of 2020 Exhibit 99.1 China Biologic Reports Financial Results for the Third Quarter of 2020 BEIJING, China – November 24, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2020. Third Quarter 2020 Financial Highl |
|
| November 24, 2020 |
China Biologic Third Quarter 2020 Financial Results Exhibit 99.2 China Biologic Third Quarter 2020 Financial Results Third Quarter 2020 Financial Performance Total sales in the third quarter of 2020 increased by 1.8% in USD terms, or 0.8% in RMB terms, to $138.5 million from $136.1 million in the same quarter of 2019. Total sales for biopharmaceutical products increased by 1.9% in USD terms, or 0.8% in RMB terms, to $126.6 million in the third quar |
|
| November 24, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 tm2037025d16k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong Inte |
|
| November 23, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital Advisors, Ltd. 20 Genesis Close George Town, Grand Cayman KY1-1103 Ca |
|
| November 23, 2020 |
EXHIBIT 14 Execution Version LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by Hillhouse Capital Investments Fund IV, L. |
|
| November 23, 2020 |
Exhibit 5 Execution Version LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by V-Sciences Investments Pte Ltd, a company incorporated under the Laws of the Republic of Singapore (the “Guarantor”), in favor of China Biologic Products Holdings, Inc. |
|
| November 23, 2020 |
CBPO / China Biologic Products, Inc. / Temasek Holdings (Private) Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Gregory Tan Managing Director, Legal & Regulatory Temasek International Pte. Ltd. 60B Orchard Road #06-18 T |
|
| November 20, 2020 |
CBPO / China Biologic Products, Inc. / CITIC Capital Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong |
|
| November 20, 2020 |
Exhibit 15 Execution Version LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by CC China (2019B) L. |
|
| November 20, 2020 |
SC 13D/A 1 tm2036442d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management |
|
| November 20, 2020 |
Exhibit 3 Execution Version AMENDED AND RESTATED CONSORTIUM AGREEMENT This AMENDED AND RESTATED CONSORTIUM AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2020, by and among Beachhead Holdings Limited (“Beachhead”), Double Double Holdings Limited (“Double Double”), Point Forward Holdings Limited (“Point Forward,” and together with Beachhead, Double Double, and any of their respective Affiliates who becomes a party to this Agreement, collectively, “Centurium”), CITIC Capital China Partners IV, L. |
|
| November 20, 2020 |
EX-14 2 tm2036536d1ex14.htm EXHIBIT 14 Exhibit 14 Execution Version LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by CITIC Capital China Partners IV, L.P., an exempted limited partnership formed under the Laws of the Cayman Islands (the “Guarantor”), in favor of China Biologic Products Holdings, Inc., an exempted company incorporated wi |
|
| November 20, 2020 |
Exhibit 16 Execution Version EQUITY COMMITMENT LETTER November 19, 2020 CBPO Holdings Limited PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands Ladies and Gentlemen: This letter agreement sets forth the commitment of CC China (2019B) L. |
|
| November 20, 2020 |
Exhibit 99.5 Execution Version LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by Marc Chan, a Canadian citizen (the “Guarantor”), in favor of China Biologic Products Holdings, Inc., an exempted company incorporated with limited liability under the Laws of the Cayman Islands (the “Guaranteed Party”). This Limited Guarantee is being delive |
|
| November 20, 2020 |
CBPO / China Biologic Products, Inc. / PW Medtech Group Ltd - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong +86 10 8478 |
|
| November 20, 2020 |
EX-99.33 2 tm2036529d1ex33.htm EXHIBIT 33 Exhibit 33 To: CBPO Holdings Limited (“Parent”) c/o Maples Corporate Services Limited PO Box 309, Ugland House Grand Cayman, KY1-1104, Cayman Islands November 19, 2020 Dear Sirs, Re: Voting undertakings regarding a proposed acquisition of China Biologic Products Holdings, Inc. (the “Company”) We, PW Medtech Group Limited (普华和顺集团公司) (“we,” “us,” or “our”), |
|
| November 20, 2020 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment SC 13D/A 1 sc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G215151 |
|
| November 20, 2020 |
Exhibit 99.21 EQUITY COMMITMENT LETTER November 19, 2020 CBPO Holdings Limited PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands Ladies and Gentlemen: This letter agreement sets forth the commitment of Biomedical Treasure Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Sponsor”), subject to the terms and conditions contained here |
|
| November 20, 2020 |
Exhibit 99.20 LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by Biomedical Treasure Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Guarantor”), in favor of China Biologic Products Holdings, Inc., an exempted company incorporated with limited liability under the Laws of the Caym |
|
| November 20, 2020 |
Exhibit 4 Execution Version LIMITED GUARANTEE This LIMITED GUARANTEE, dated as of November 19, 2020 (this “Limited Guarantee”), is made by Centurium Capital Partners 2018, L. |
|
| November 20, 2020 |
Exhibit 2 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2020, by and among CBPO Holdings Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”), the persons listed in the column titled “Rollover Securityholder” on Schedule A hereto (each, a “Ro |
|
| November 20, 2020 |
Exhibit 1 Execution Version AGREEMENT AND PLAN OF MERGER Among CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. |
|
| November 20, 2020 |
CBPO / China Biologic Products, Inc. / Chow Joseph - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 China Biologic Products Holdings, Inc. (Name of issuer) Ordinary Shares, par value US$0.0001 per share (Title of |
|
| November 19, 2020 |
Exhibit 99.2 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER Among CHINA BIOLOGIC PRODUCTS HOLDINGS, INC., CBPO HOLDINGS LIMITED and CBPO GROUP LIMITED Dated as of November 19, 2020 TABLE OF CONTENTS Page Article I THE MERGER Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effect of the Merger 3 Section 1.5 Company Memorandum and Articles of Association 3 Sec |
|
| November 19, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoy |
|
| November 19, 2020 |
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction Exhibit 99.1 China Biologic Enters into Definitive Merger Agreement for Going Private Transaction BEIJING, China – November 19, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agr |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 4) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934 China Biologic Products Holdings, Inc. (Name of the Issuer) Beachhead Holdings Limited Double Double Holdings Limited Point Forward Holdings Limited Centurium Capital Partners 2018, L.P. Centurium Capita |
|
| November 10, 2020 |
Exhibit (d)-(33) Execution Version CC CHINA (2019B) L.P. c/o Walkers Corporate Limited Cayman Corporate Centre, 27 Hospital Road, George Town Grand Cayman KY1-9008, Cayman Islands 23 September 2020 Lachesis Biologics Limited Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands RE: Investment in CC China (2019B) L.P. Ladies and Gentlemen: This letter a |
|
| October 29, 2020 |
CBPO / China Biologic Products, Inc. / Chow Joseph - SC 13D/A Activist Investment AMENDMENT NO. 1 TO SCHEDULE 13D CUSIP No. G21515104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 China Biologic Products Holdings, Inc. (Name of issuer) Ordi |
|
| October 28, 2020 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Nam |
|
| October 28, 2020 |
Letter Agreement between Parfield and 2019B Cayman Limited dated October 26, 2020. Execution Version LETTER AGREEMENT October 26, 2020 2019B Cayman Limited 27 Hospital Road, George Town Grand Cayman KY1-9008 Cayman Islands Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) sets forth the agreement by and among Parfield International Ltd. |
|
| October 28, 2020 |
Exhibit 99.3 EXECUTION VERSION AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of October 26, 2020, is entered into by and among Parfield International Ltd., a British Virgin Islands company (“Parfield”), Amplewood Resources Ltd., a British Virgin Islands company (“Amplewood,” together with Parfield, collectively, the “Selle |
|
| October 28, 2020 |
Share Purchase Agreement between Parfield and 2019B Cayman Limited dated October 26, 2020. Exhibit 99.4 Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and among Parfield International Ltd., a British Virgin Islands company (the “Seller”) and 2019B Cayman Limited, a Cayman Islands company (the “Purchaser,” and together with the Seller, each a “Party” and collectively, the “Parties”). Capitalized terms used but |
|
| October 28, 2020 |
Management Adherence Deed dated October 26, 2020. EX-99.2 2 ex99-2.htm Exhibit 99.2 PRIVILEGED and CONFIDENTIAL Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on October 26, 2020 BY: (a) Biomedical Treasure Limited (“Biomedical Treasure”), an exempted company with limited liability organized and existing under the Laws of Cayman Islands; (b) Biomedical Future Limited (“Biomedical Future”), an exempted com |
|
| October 28, 2020 |
SC 13D/A 1 p20-1926sc13da.htm CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital |
|
| October 28, 2020 |
PWM SPA Amendment No. 3, dated as of October 26, 2020, by and between PWM and Double Double. EX-99.16 3 tm2034459d1ex16.htm EXHIBIT 16 Exhibit 16 AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of October 26, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Double Double Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the Seller and Bea |
|
| October 28, 2020 |
SC 13D/A 1 tm2034255d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management |
|
| October 28, 2020 |
EX-99.27 14 tm2034459d1ex27.htm EXHIBIT 27 Exhibit 27 IRREVOCABLE UNDERTAKING To: PW Medtech Group Limited (普华和顺集团公司) (the “Company”) PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East, Hong Kong Attention: The Board of Directors October 26, 2020 Dear Sirs Re: Share Transfer in China Biologic Products Holdings, Inc. (the “Target”) WHEREAS, on the date hereof, the Company and |
|
| October 28, 2020 |
Exhibit 22 LETTER AGREEMENT October 26, 2020 Biomedical Treasure Limited PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands CPEChina Fund III, L. |
|
| October 28, 2020 |
EX-99.2 3 tm2034255d1ex2.htm EXHIBIT 2 Exhibit 2 STRICTLY CONFIDENTIAL Execution version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and Biomedical Development Limited, a Cayman Islands company (the “Purchaser”). The Seller and the Purchaser shall be r |
|
| October 28, 2020 |
Exhibit 4 EXECUTION VERSION AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of October 26, 2020, is entered into by and among Parfield International Ltd., a British Virgin Islands company (“Parfield”), Amplewood Resources Ltd., a British Virgin Islands company (“Amplewood,” together with Parfield, collectively, the “Seller”) |
|
| October 28, 2020 |
Exhibit 17 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Biomedical Treasure Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Purchaser,” and together with the Seller, each a “Party” and collectively, the “Parties”). |
|
| October 28, 2020 |
Exhibit 10 Execution Version LETTER AGREEMENT October 26, 2020 2019B Cayman Limited 27 Hospital Road, George Town Grand Cayman KY1-9008 Cayman Islands Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) sets forth the agreement by and among Parfield International Ltd. |
|
| October 28, 2020 |
EX-99.1 2 tm2034255d1ex1.htm EXHIBIT 1 Exhibit 1 PRIVILEGED and CONFIDENTIAL Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on October 26, 2020 BY: (a) Biomedical Treasure Limited (“Biomedical Treasure”), an exempted company with limited liability organized and existing under the Laws of Cayman Islands; (b) Biomedical Future Limited (“Biomedical Future”), |
|
| October 28, 2020 |
Exhibit 20 ASSIGNMENT AND AMENDMENT AGREEMENT THIS ASSIGNMENT AND AMENDMENT AGREEMENT (this “Assignment”) is made and entered into as of October 26, 2020, by and among China Biologic Products Holdings, Inc. |
|
| October 28, 2020 |
Exhibit 28 IRREVOCABLE UNDERTAKING To: PW Medtech Group Limited (普华和顺集团公司) (the “Company”) PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East, Hong Kong Attention: The Board of Directors October 26, 2020 Dear Sirs Re: Share Transfer in China Biologic Products Holdings, Inc. |
|
| October 28, 2020 |
Exhibit 21 ASSIGNMENT AND AMENDMENT AGREEMENT THIS ASSIGNMENT AND AMENDMENT AGREEMENT (this “Assignment”) is made and entered into as of October 26, 2020, by and among China Biologic Products Holdings, Inc. |
|
| October 28, 2020 |
Exhibit 24 LETTER AGREEMENT October 26, 2020 Biomedical Future Limited PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands Neptune Connection Limited 17/F CITIC Securities Tower No. |
|
| October 28, 2020 |
PWM Supplemental Agreement, dated as of October 26, 2020, by and between PWM and the Issuer. Exhibit 30 SUPPLEMENTAL AGREEMENT This SUPPLEMENTAL AGREEMENT (this “Agreement”), dated as of October 26, 2020, is entered into by and between China Biologic Products Holdings, Inc. |
|
| October 28, 2020 |
Exhibit 8 EXECUTION VERSION LETTER AGREEMENT October 26, 2020 2019B Cayman Limited 27 Hospital Road, George Town Grand Cayman KY1-9008 Cayman Islands Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) sets forth the agreement by and among PW Medtech Group Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“PWM”), and 2019B Cayman Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“2019B Cayman,” and together with PWM, each a “Party” and collectively, the “Parties”) in relation to the Take Private Transaction (as defined below). |
|
| October 28, 2020 |
PWM SPA Amendment No. 3, dated as of October 26, 2020, by and between PWM and Point Forward. Exhibit 15 AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of October 26, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Point Forward Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the Seller and Beachhead Holdings Limited, a Cayman Islands |
|
| October 28, 2020 |
Management Adherence Deed, dated as of October 26, 2020, by BTL, BFL and BDL. Exhibit 25 PRIVILEGED and CONFIDENTIAL Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on October 26, 2020 BY: (a) Biomedical Treasure Limited (“Biomedical Treasure”), an exempted company with limited liability organized and existing under the Laws of Cayman Islands; (b) Biomedical Future Limited (“Biomedical Future”), an exempted company with limited liabi |
|
| October 28, 2020 |
CBPO / China Biologic Products, Inc. / PW Medtech Group Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong +86 10 8478 |
|
| October 28, 2020 |
Exhibit 26 IRREVOCABLE UNDERTAKING To: PW Medtech Group Limited (普华和顺集团公司) (the “Company”) PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East, Hong Kong Attention: The Board of Directors October 26, 2020 Dear Sirs Re: Share Transfer in China Biologic Products Holdings, Inc. |
|
| October 28, 2020 |
SC 13D/A 1 tm2034471-1sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, |
|
| October 28, 2020 |
Exhibit 3 EXECUTION VERSION AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of October 26, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Point Forward Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the Seller and Beachhead Holdings Limited, |
|
| October 28, 2020 |
Exhibit 29 IRREVOCABLE UNDERTAKING To: PW Medtech Group Limited (普华和顺集团公司) (the “Company”) PW Medtech Group Limited Level 54, Hopewell Centre 183 Queen’s Road East, Hong Kong Attention: The Board of Directors October 26, 2020 Dear Sirs Re: Acquisition Transaction with Respect to China Biologic Products Holdings, Inc. |
|
| October 28, 2020 |
EX-99.19 6 tm2034459d1ex19.htm EXHIBIT 19 Exhibit 19 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Biomedical Future Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Purchaser,” and together with the |
|
| October 28, 2020 |
Exhibit 18 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and 2019B Cayman Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Purchaser,” and together with the Seller, each a “Party” and collectively, the “Parties”). |
|
| October 28, 2020 |
Exhibit 9 Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and among Parfield International Ltd. |
|
| October 28, 2020 |
Exhibit 7 EXECUTION VERSION SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of October 26, 2020 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and 2019B Cayman Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Purchaser,” and together with the Seller, each a “Party” and collectively, the “Parties”). |
|
| October 28, 2020 |
Exhibit 23 LETTER AGREEMENT October 26, 2020 2019B Cayman Limited 27 Hospital Road, George Town Grand Cayman KY1-9008 Cayman Islands Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) sets forth the agreement by and among PW Medtech Group Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“PWM”), and 2019B Cayman Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“2019B Cayman,” and together with PWM, each a “Party” and collectively, the “Parties”) in relation to the Take Private Transaction (as defined below). |
|
| September 23, 2020 |
CBPO / China Biologic Products, Inc. / Chow Joseph - SCHEDULE 13D Activist Investment SCHEDULE 13D CUSIP No. G21515104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 China Biologic Products Holdings, Inc. (Name of issuer) Ordinary Shares, par value US$0.0001 per |
|
| September 18, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital Advisors, Ltd. 20 Genesis Close George Town, Grand Cayman KY1-1103 Ca |
|
| September 18, 2020 |
Exhibit 3 Execution Version To: Parties listed on the signature pages hereto September 16, 2020 Re: Exclusivity Period References are made in this letter (this “Letter”) to (i) the preliminary non-binding proposal, dated as of September 18, 2019, to acquire for cash all of the ordinary shares of China Biologic Products Holdings, Inc. |
|
| September 18, 2020 |
EXHIBIT 1 The name, present principal occupation and business address of each director and executive officer of the Reporting Persons is set forth below. |
|
| September 18, 2020 |
Exhibit 4 Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on September 16, 2020 BY: Mr. |
|
| September 18, 2020 |
CBPO / China Biologic Products, Inc. / Temasek Holdings (Private) Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Ang Lye Whatt Director, Legal & Regulatory Temasek International Pte. Ltd. 60B Orchard Road #06-18 T |
|
| September 17, 2020 |
Exhibit 99.3 STRICTLY CONFIDENTIAL Execution Version To: Parties listed on the signature pages hereto September 16, 2020 Re: Exclusivity Period References are made in this letter (this “Letter”) to (i) the preliminary non-binding proposal, dated as of September 18, 2019, to acquire for cash all of the ordinary shares of China Biologic Products Holdings, Inc. (the “Company”) not currently owned by |
|
| September 17, 2020 |
Exhibit 1 STRICTLY CONFIDENTIAL Execution Version To: Parties listed on the signature pages hereto September 16, 2020 Re: Exclusivity Period References are made in this letter (this “Letter”) to (i) the preliminary non-binding proposal, dated as of September 18, 2019, to acquire for cash all of the ordinary shares of China Biologic Products Holdings, Inc. |
|
| September 17, 2020 |
Chairman Adherence Deed, dated as of September 16, 2020, by Mr. Chow. Exhibit 13 PRIVILEGED and CONFIDENTIAL Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on September 16, 2020 BY: Mr. |
|
| September 17, 2020 |
Exclusivity Extension Letter, dated September 16, 2020 by and among the Buyer Consortium. Exhibit 14 STRICTLY CONFIDENTIAL Execution Version To: Parties listed on the signature pages hereto September 16, 2020 Re: Exclusivity Period References are made in this letter (this “Letter”) to (i) the preliminary non-binding proposal, dated as of September 18, 2019, to acquire for cash all of the ordinary shares of China Biologic Products Holdings, Inc. |
|
| September 17, 2020 |
SC 13D/A 1 tm2030967d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management |
|
| September 17, 2020 |
CBPO / China Biologic Products, Inc. / CITIC Capital Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong |
|
| September 17, 2020 |
Exhibit 2 PRIVILEGED and CONFIDENTIAL Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on September 16, 2020 BY: Mr. |
|
| September 17, 2020 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Parf |
|
| September 17, 2020 |
Exhibit 99.2 PRIVILEGED and CONFIDENTIAL Execution Version Deed of Adherence This Deed of Adherence (this “Deed”) is entered into on September 16, 2020 BY: Mr. Joseph Chow (“Mr. Chow”), a citizen of the United States of America RECITALS: (A) On September 18, 2019, that certain consortium agreement (as amended by amendment no. 1 thereto (the “Amendment No. 1”) dated as of January 23, 2020, the “Con |
|
| September 17, 2020 |
CBPO / China Biologic Products, Inc. / PW Medtech Group Ltd - SC 13D/A Activist Investment SC 13D/A 1 tm2030965d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Level 54, Hopewell Centre 18 |
|
| August 17, 2020 |
China Biologic Reports Financial Results for the Second Quarter of 2020 EX-99.1 2 tm2028761d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 China Biologic Reports Financial Results for the Second Quarter of 2020 BEIJING, China – August 17, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarte |
|
| August 17, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2028761d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong I |
|
| August 17, 2020 |
China Biologic Second Quarter 2020 Financial Results EX-99.2 3 tm2028761d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 China Biologic Second Quarter 2020 Financial Results Second Quarter 2020 Financial Performance Total sales in the second quarter of 2020 decreased by 18.1% in USD terms, or 14.9% in RMB terms, to $111.1 million from $135.7 million in the same quarter of 2019. Total sales for biopharmaceutical products decreased by 20.3% in USD terms, or 17. |
|
| June 29, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2023628d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong Int |
|
| June 29, 2020 |
China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction Exhibit 99.1 FOR RELEASE June 29, 2020 China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction BEIJING, China – June 29, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered b |
|
| May 20, 2020 |
China Biologic First Quarter 2020 Financial Results Exhibit 99.2 China Biologic First Quarter 2020 Financial Results First Quarter 2020 Financial Performance Total sales in the first quarter of 2020 increased by 25.3% in USD terms, or 29.4% in RMB terms, to $162.6 million from $129.8 million in the same quarter of 2019. Total sales for biopharmaceutical products increased by 31.3% in USD terms, or 35.7% in RMB terms, to $153.0 million in the first |
|
| May 20, 2020 |
China Biologic Reports Financial Results for the First Quarter of 2020 Exhibit 99.1 China Biologic Reports Financial Results for the First Quarter of 2020 BEIJING, China – May 20, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2020. First Quarter 2020 Financial Highlights |
|
| May 20, 2020 |
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction EX-99.3 4 tm2020190d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 FOR RELEASE May 20, 2020 China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction BEIJING, China – May 20, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that Xinjiang Deyuan Bioenginee |
|
| May 20, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang P |
|
| May 11, 2020 |
CBPO / China Biologic Products, Inc. / Pw Medtech Group Ltd - SC 13D/A Activist Investment SC 13D/A 1 tm2019230d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Building 1, No. 23 Panlong W |
|
| May 8, 2020 |
S-8 1 tm2018943d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on May 8, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) Cayman Islands 75-2308816 (State or other juri |
|
| May 8, 2020 |
SC 13D/A 1 p20-0978sc13da.htm CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Qu |
|
| May 7, 2020 |
EX-99.1 2 tm2018942d1ex-1.htm EXHIBIT 1 Exhibit 1 AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of May 5, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the parties hereto entered int |
|
| May 5, 2020 |
AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT EX-12 2 tm2018625d1ex12.htm EXHIBIT 12 Exhibit 12 AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of May 5, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the parties hereto entered int |
|
| May 5, 2020 |
CBPO / China Biologic Products, Inc. / Pw Medtech Group Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Building 1, No. 23 Panlong West Road Pinggu District, Beijing People’s |
|
| May 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Qu |
|
| April 24, 2020 |
SC 13E3/A 1 tm2015225-1sc13e3a.htm SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 3) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934 China Biologic Products Holdings, Inc. (Name of the Issuer) Beachhead Holdings Limited Double Double Holdings Limited Point Forward Holdings Limited Centurium |
|
| April 14, 2020 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment SC 13D/A 1 sc-13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515 |
|
| April 10, 2020 |
Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Ordinary Shares, par value $0. |
|
| April 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Qu |
|
| April 8, 2020 |
SC 13D/A 1 tm2015361-1sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, |
|
| April 8, 2020 |
Joint Filing Agreement, dated April 8, 2020, by and among the Reporting Persons EX-99.1 2 tm2015361d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all additional amendments thereto) with respect to the ordinary shares of China Biologic Products Holdings, Inc. and further |
|
| March 30, 2020 |
Centurium Capital Partners 2018, L.p. SC 13E3/A - - SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 2) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934 China Biologic Products Holdings, Inc. (Name of the Issuer) Beachhead Holdings Limited Double Double Holdings Limited Point Forward Holdings Limited Centurium Capital Partners 2018, L.P. Centurium Capita |
|
| March 20, 2020 |
AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT Exhibit 11 AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of March 17, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the parties hereto entered into a share purchase agreement dated a |
|
| March 20, 2020 |
Exhibit 2 Execution Version AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of March 17, 2020, is entered into by and between PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser”). WHEREAS, the parties hereto entered into a share purchase |
|
| March 20, 2020 |
Exhibit 99.2 Parfield SPA Amendment No. 1 dated March 17, 2020 by Parfield, Amplewood and Beachhead. Execution Version AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT (this “Amendment”),dated as of March 17, 2020, is entered into by and among Parfield International Ltd., a British Virgin Islands company (“Parfield”), and Amplewood Resources Ltd., a Brit |
|
| March 20, 2020 |
Exhibit 3 Execution Version AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SHARE PURCHASE AGREEMENT (this “Amendment”), dated as of March 17, 2020, is entered into by and among Parfield International Ltd., a British Virgin Islands company (“Parfield”), and Amplewood Resources Ltd., a British Virgin Islands company (“Amplewood,” together with Parfield, collectively, the “Seller |
|
| March 20, 2020 |
EX-99.1 2 tm2013100d1ex1.htm EXHIBIT 1 Exhibit 1 Specific terms in this Exhibit have been redacted because confidential treatment for those terms has been requested. The redacted material has been separately filed with the Securities and Exchange Commission, and the terms have been marked at the appropriate places with three asterisks [***] HOLDCO FACILITY AGREEMENT DATED 14 February 2020 for BEAC |
|
| March 20, 2020 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Nam |
|
| March 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Que |
|
| March 20, 2020 |
CBPO / China Biologic Products, Inc. / Pw Medtech Group Ltd - SC 13D/A Activist Investment SC 13D/A 1 tm2013092-1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Building 1, No. 23 Panlong W |
|
| March 12, 2020 |
China Biologic Fourth Quarter and Fiscal Year 2019 Financial Results EX-99.2 3 tm2012199d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 China Biologic Fourth Quarter and Fiscal Year 2019 Financial Results Fourth Quarter 2019 Financial Performance Total sales in the fourth quarter of 2019 decreased by 9.6% in RMB terms, or 11.1% in USD terms, to $102.2 million from $114.9 million in the same quarter of 2018. Total sales for plasma products increased by 2.7% in RMB terms, or |
|
| March 12, 2020 |
Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of China Biologic Products Holdings, Inc. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ming Yang, Chief Financial Officer of the Compan |
|
| March 12, 2020 |
Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Joseph Chow, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to mak |
|
| March 12, 2020 |
Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of China Biologic Products Holdings, Inc. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Chow, Chairman of the Board of Directors |
|
| March 12, 2020 |
Employment Agreement between the Company and Joseph Chow dated August 16, 2019 EXHIBIT 4.40 Employment Agreement This Employment Agreement (this “Agreement”), dated as of August 16, 2019, is entered into between China Biologic Products Holdings, Inc., a company established in the Cayman Islands with its principal office located at 18th Floor, Jialong Int’l Tower, 19 Chaoyang Park Road, Beijing 100125, PRC (“Company”), and Joseph Chow (the “Executive”). WHEREAS, the Company d |
|
| March 12, 2020 |
CPBO / 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang |
|
| March 12, 2020 |
EXHIBIT 2.8 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 China Biologic Products Holdings, Inc. (the “Company,” “we,” “us” or “our”) has two classes of securities registered under Section 12(b) of the Securities Exchange Act of 1934: (i) our ordinary shares, par value $0.0001 per share and (2) our preferred share purchase righ |
|
| March 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| March 12, 2020 |
Consent of independent registered public accounting firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors China Biologic Products Holdings, Inc. We consent to the incorporation by reference in the Registration Statement (No. 333-151263) on Form S-8 (as amended by Post-Effective Amendment No. 1) of China Biologic Products Holdings, Inc. (the “Company”) of our reports dated March 12, 2020, with respect to the co |
|
| March 12, 2020 |
Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| March 12, 2020 |
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019 EX-99.1 2 tm2012199d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019 BEIJING, China – March 12, 2020 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quar |
|
| February 19, 2020 |
Centurium Capital Partners 2018, L.p. SC 13E3/A - - SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 1) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934 China Biologic Products Holdings, Inc. (Name of the Issuer) Beachhead Holdings Limited Double Double Holdings Limited Point Forward Holdings Limited Centurium Capital Partners 2018, L.P. Centurium Capita |
|
| February 19, 2020 |
Exhibit (d)-(6) Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and 2019B Cayman Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Purchaser”). |
|
| February 19, 2020 |
EX-99.(D)(5) 6 tm207907d3ex-d5.htm EXHIBIT (D)(5) Exhibit (d)-(5) STRICTLY CONFIDENTIAL Executive Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of September 18, 2019 (this “Agreement”), by and among Parfield International Ltd., a British Virgin Islands company (“Parfield”), and Amplewood Resources Ltd., a British Virgin Islands company (“Amplewood,” together with Parfiel |
|
| February 19, 2020 |
Exhibit (d)-(3) Execution Version AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT This AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT, dated as of January 23, 2020 (this “Amendment”), is entered by and among Beachhead Holdings Limited (“Beachhead”), Double Double Holdings Limited (“Double Double”), Point Forward Holdings Limited (“Point Forward,” and together with Beachhead and Double Double, collectively, “Cent |
|
| February 19, 2020 |
Share Purchase Agreement, dated as of January 23, 2020, by and between Double Double and V-Sciences. Exhibit (d)-(8) Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and V-Sciences Investments Pte Ltd, a private limited company incorporated under the laws of the Republic of Singapore (the “Purchaser”). |
|
| February 19, 2020 |
Share Purchase Agreement, dated as of September 18, 2019, by and between PWM and Beachhead. Exhibit (d)-(4) STRICTLY CONFIDENTIAL Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of September 18, 2019 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser” together with the Seller, each a “Party” and collectively, the “Parties”). |
|
| February 19, 2020 |
Share Purchase Agreement, dated as of January 23, 2020, by and between Double Double and HH Sum. Exhibit (d)-(7) Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and HH Sum-XXII Holdings Limited, a Cayman Islands company (the “Purchaser”). |
|
| February 19, 2020 |
Exhibit (d)-(2) PREVILEDGED AND CONFIDENTIAL Execution Version CONSORTIUM AGREEMENT This CONSORTIUM AGREEMENT (this “Agreement”) is made and entered into as of September 18, 2019, by and among Beachhead Holdings Limited (“Centurium”), PW Medtech Group Limited (普华和顺集团公司) (“PWM”), CITIC Capital China Partners IV, L. |
|
| February 19, 2020 |
Proposal from Beachhead, PWM, CCCP IV, Parfield, HH Sum and V-Sciences, dated September 18, 2019. Exhibit (d)-(1) Preliminary Non-binding Proposal to Acquire China Biologic Products Holdings, Inc. |
|
| January 27, 2020 |
CBPO / China Biologic Products, Inc. / Hillhouse Capital Advisors, Ltd. Activist Investment SC 13D/A 1 p20-0285sc13da.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital Advisors, Ltd. 20 Genesis Close George |
|
| January 24, 2020 |
CBPO / China Biologic Products, Inc. / CITIC Capital Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong |
|
| January 24, 2020 |
EX-99.2 3 tm205537d1ex2.htm EXHIBIT 2 Exhibit 2 Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and 2019B Cayman Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Purchaser”). The Seller and the |
|
| January 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Que |
|
| January 24, 2020 |
EX-99.1 2 tm205537d1ex1.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments |
|
| January 24, 2020 |
EX-99.5 6 tm205537d1ex5.htm EXHIBIT 5 Exhibit 5 Execution Version AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT This AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT, dated as of January 23, 2020 (this “Amendment”), is entered by and among Beachhead Holdings Limited (“Beachhead”), Double Double Holdings Limited (“Double Double”), Point Forward Holdings Limited (“Point Forward,” and together with Beachhead and Do |
|
| January 24, 2020 |
Exhibit 4 Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and V-Sciences Investments Pte Ltd, a private limited company incorporated under the laws of the Republic of Singapore (the “Purchaser”). |
|
| January 24, 2020 |
EX-99.3 4 tm205537d1ex3.htm EXHIBIT 3 Exhibit 3 Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and HH Sum-XXII Holdings Limited, a Cayman Islands company (the “Purchaser”). The Seller and the Purchaser shall be referred to hereinafter co |
|
| January 24, 2020 |
AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT EX-10 2 tm1924876d1ex10.htm EXHIBIT 10 Exhibit 10 AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT This AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT, dated as of January 23, 2020 (this “Amendment”), is entered by and among Beachhead Holdings Limited (“Beachhead”), Double Double Holdings Limited (“Double Double”), Point Forward Holdings Limited (“Point Forward,” and together with Beachhead and Double Double, col |
|
| January 24, 2020 |
EXHIBIT 1 The name, present principal occupation and business address of each director and executive officer of the Reporting Persons is set forth below. |
|
| January 24, 2020 |
EXHIBIT 3 Execution Version AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT This AMENDMENT NO. 1 TO CONSORTIUM AGREEMENT, dated as of January 23, 2020 (this “Amendment”), is entered by and among Beachhead Holdings Limited (“Beachhead”), Double Double Holdings Limited (“Double Double”), Point Forward Holdings Limited (“Point Forward,” and together with Beachhead and Double Double, collectively, “Centurium” |
|
| January 24, 2020 |
EX-99.2 3 ex992.htm EXHIBIT 2 EXHIBIT 2 Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of January 23, 2020 (this “Agreement”), by and between Double Double Holdings Limited, a Cayman Islands company (the “Seller”) and V-Sciences Investments Pte Ltd, a private limited company incorporated under the laws of the Republic of Singapore (the “Purchaser”). The Seller a |
|
| January 24, 2020 |
CBPO / China Biologic Products, Inc. / Pw Medtech Group Ltd - SCHEDULE 13D/A Activist Investment SC 13D/A 1 tm1924876-1sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Building 1, No. 23 Pan |
|
| January 24, 2020 |
CBPO / China Biologic Products, Inc. / Temasek Holdings (Private) Ltd - SC 13D/A Activist Investment SC 13D/A 1 formsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Ang Lye Whatt Director, Legal & Regulatory Temasek International |
|
| November 18, 2019 |
EX-99.2 3 tm1923050d1ex2.htm EXHIBIT 2 Exhibit 2 STRICTLY CONFIDENTIAL Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of November 15, 2019 (this “Agreement”), by and among the persons listed on Schedule A hereto (each, a “Seller” and collectively, the “Sellers”), Beachhead Holdings Limited, a Cayman Islands company (“Beachhead”) and Double Double Holdings Limite |
|
| November 18, 2019 |
EX-99.1 2 tm1923050d1ex1.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments |
|
| November 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Que |
|
| November 13, 2019 |
China Biologic Third Quarter 2019 Financial Results Exhibit 99.2 China Biologic Third Quarter 2019 Financial Results Third Quarter 2019 Financial Performance Total sales in the third quarter of 2019 increased by 17.5% in RMB terms, or 14.3% in USD terms, to $136.1 million from $119.1 million in the same quarter of 2018. Total sales for biopharmaceutical products (including plasma products and placenta polypeptide products) increased by 18.8% in RMB |
|
| November 13, 2019 |
CBPO / China Biologic Products, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoy |
|
| November 13, 2019 |
China Biologic Reports Financial Results for the Third Quarter of 2019 Exhibit 99.1 China Biologic Reports Financial Results for the Third Quarter of 2019 BEIJING, China – November 13, 2019 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2019. Third Quarter 2019 Financial Highl |
|
| November 6, 2019 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Nam |
|
| November 6, 2019 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Ordinary Shares, $0.0001 par value, of China Biologic Products Holdings, Inc. This Joint |
|
| October 17, 2019 |
CBPO / China Biologic Products, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoya |
|
| October 17, 2019 |
China Biologic Special Committee Retains Financial Advisor and Legal Counsel Exhibit 99.1 FOR RELEASE October 17, 2019 China Biologic Special Committee Retains Financial Advisor and Legal Counsel BEIJING, China – October 17, 2019 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the special committee (the “Special Committee”) of the Com |
|
| September 30, 2019 |
EX-99.2 2 ex992.htm EXHIBIT 2 EXHIBIT 2 The name, present principal occupation and business address of each director and executive officer of the Reporting Persons is set forth below. The following is a list of the executive officers and directors of Temasek Holdings (Private) Limited: Name, Business Address, Position Principal Occupation Citizenship Lim Boon Heng 60B Orchard Road #06-18 Tower 2 T |
|
| September 30, 2019 |
EXHIBIT 6 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the ordinary shares of China Biologic Products Holdings, Inc. |
|
| September 30, 2019 |
CBPO / China Biologic Products, Inc. / Temasek Holdings (Private) Ltd - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Ang Lye Whatt Director, Legal & Regulatory Temasek International Pte. Ltd. 60B Orchard Road #06-18 To |
|
| September 27, 2019 |
Exhibit 99.3 STRICTLY CONFIDENTIAL Executive Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of September 18, 2019 (this “Agreement”), by and among Parfield International Ltd., a British Virgin Islands company (“Parfield”), and Amplewood Resources Ltd., a British Virgin Islands company (“Amplewood,” together with Parfield, collectively, the “Seller”), and Beachhead Holding |
|
| September 27, 2019 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 * China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Parfield International Ltd. |
|
| September 27, 2019 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PREVILEDGED AND CONFIDENTIAL Execution Version CONSORTIUM AGREEMENT This CONSORTIUM AGREEMENT (this “Agreement”) is made and entered into as of September 18, 2019, by and among Beachhead Holdings Limited (“Centurium”), PW Medtech Group Limited (普华和顺集团公司) (“PWM”), CITIC Capital China Partners IV, L.P., represented by its general partner CCP IV GP Ltd. (“CITIC”), Pa |
|
| September 24, 2019 |
CBPO / China Biologic Products, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chao |
|
| September 24, 2019 |
China Biologic Forms Special Committee to Review “Going Private” Proposal EX-99.1 2 tv529983ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR RELEASE September 24, 2019 China Biologic Forms Special Committee to Review “Going Private” Proposal BEIJING, China – September 24, 2019 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of di |
|
| September 20, 2019 |
CBPO / China Biologic Products, Inc. / CITIC Capital Holdings Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Eric Chan CITIC Capital Holdings Limited 28/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong |
|
| September 19, 2019 |
CBPO / China Biologic Products, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chao |
|
| September 19, 2019 |
China Biologic Announces Receipt of Preliminary Non-Binding “Going Private” Proposal EX-99.1 2 tv529744ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR RELEASE September 18, 2019 China Biologic Announces Receipt of Preliminary Non-Binding “Going Private” Proposal BEIJING, China – September 18, 2019 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its |
|
| September 19, 2019 |
EX-99.1 2 tv529741ex1.htm EXHIBIT 1 Exhibit 1 PREVILEDGED AND CONFIDENTIAL Execution Version CONSORTIUM AGREEMENT This CONSORTIUM AGREEMENT (this “Agreement”) is made and entered into as of September 18, 2019, by and among Beachhead Holdings Limited (“Centurium”), PW Medtech Group Limited (普华和顺集团公司) (“PWM”), CITIC Capital China Partners IV, L.P., represented by its general partner CCP IV GP Ltd. ( |
|
| September 19, 2019 |
EX-99.3 3 tv529741ex3.htm EXHIBIT 3 Exhibit 3 STRICTLY CONFIDENTIAL Execution Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of September 18, 2019 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser” together with the Seller, each a “Party” and collectiv |
|
| September 19, 2019 |
Exhibit 4 STRICTLY CONFIDENTIAL Executive Version SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of September 18, 2019 (this “Agreement”), by and among Parfield International Ltd. |
|
| September 19, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) Richard A. Hornung Hillhouse Capital Advisors, Ltd. 20 Genesis Close George Town, Grand Cayman KY1-1103 Cayman |
|
| September 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Management Ltd. Suite 1008, Two Pacific Place, 88 Que |
|
| September 19, 2019 |
EX-99.9 3 tv529758ex99-9.htm EXHIBIT 99.9 Exhibit 9 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of September 18, 2019 (this “Agreement”), by and among PW Medtech Group Limited, a Cayman Islands company (the “Seller”) and Beachhead Holdings Limited, a Cayman Islands company (the “Purchaser” together with the Seller, each a “Party” and collectively, the “Parties”). Capitalized t |
|
| September 19, 2019 |
CBPO / China Biologic Products, Inc. / Pw Medtech Group Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) George Chen PW Medtech Group Limited Building 1, No. 23 Panlong West Road Pinggu District, Beijing People’s |
|
| September 19, 2019 |
Exhibit 8 CONSORTIUM AGREEMENT This CONSORTIUM AGREEMENT (this “Agreement”) is made and entered into as of September 18, 2019, by and among Beachhead Holdings Limited (“Centurium”), PW Medtech Group Limited (普华和顺集团公司) (“PWM”), CITIC Capital China Partners IV, L. |
|
| August 5, 2019 |
EX-99.1 2 tv526730ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR RELEASE August 5, 2019 China Biologic Reports Financial Results for the Second Quarter of 2019 —2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms — —1H19 Total Sales Up 14.0% YoY in USD terms, or 21.3% YoY in RMB terms; Net |
|
| August 5, 2019 |
CBPO / China Biologic Products, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyan |
|
| June 28, 2019 |
CBPO / China Biologic Products, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang |
|
| May 15, 2019 |
Exhibit 99.1 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 28, 2019 Dear Shareholder: Notice is hereby given that the annual general meeting of shareholders (the “Annual Meeting”) of China Biologic Products Holdings, Inc., an exempted company incorpora |
|
| May 15, 2019 |
CBPO / China Biologic Products, Inc. 6-K Current Report of Foreign Issuer FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang P |
|
| May 10, 2019 |
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. 2019 EQUITY INCENTIVE PLAN Exhibit 99.1 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes. This Plan permits the Administrator to grant Options, Restricted Shares, Restricted Share Units, Share Appreciation Rights, and Other Share-Based Awards in order to retain, attract and motivate Employees, Directors and Consultants and to provide such persons with equity ownership opportunities and performan |
|
| May 10, 2019 |
CBPO / China Biologic Products, Inc. 6-K Current Report of Foreign Issuer FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang P |
|
| May 10, 2019 |
EX-99.1 2 tv521151ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR RELEASE May 10, 2019 China Biologic Reports Financial Results for the First Quarter of 2019 —1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms — BEIJING, China – May 10, 2019 – China Biologic Products Holdings, Inc. (NASDAQ |
|
| May 10, 2019 |
CBPO / China Biologic Products, Inc. 6-K Current Report of Foreign Issuer 6-K 6-K 1 tv5211516k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong Internationa |
|
| March 12, 2019 |
SC 13D/A 1 dp103595sc13da-a5.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Manage |
|
| March 12, 2019 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Ordina |
|
| March 6, 2019 |
Exhibit 99.1 FOR RELEASE March 6, 2019 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018 -4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms - -FY18 Total Sales Up 26.1% YoY in USD terms, or 23.5% YoY in RMB terms; Net Income Up 88.7% YoY t |
|
| March 6, 2019 |
CBPO / China Biologic Products, Inc. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoyang |
|
| March 6, 2019 |
EXHIBIT 4.41 Third Amended and Restated Employment Agreement This Third Amended and Restated Employment Agreement (this “Agreement”), dated as of August 31, 2018, is entered into between China Biologic Products Holdings, Inc. (formerly known as China Biologic Products, Inc.), a company established in the Cayman Islands with its principal office located at 18th Floor, Jialong Int’l Tower, 19 Chaoya |
|
| March 6, 2019 |
Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of China Biologic Products Holdings, Inc. (the “Company”) on Form 20-F for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bing Li, Chief Executive Officer of the Company, |
|
| March 6, 2019 |
Employment Agreement between the Company and Bing Li dated August 13, 2018 EXHIBIT 4.40 Employment Agreement This Employment Agreement (this “Agreement”), dated as of August 13, 2018, is entered into between China Biologic Products Holdings, Inc., a company established in the Cayman Islands with its principal office located at 18th Floor, Jialong Int’l Tower, 19 Chaoyang Park Road, Beijing 100125, PRC (“Company”), and Bing Li (the “Executive”). WHEREAS, the Company desir |
|
| March 6, 2019 |
Exhibit 1.1 THE COMPANIES LAW (2016 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Adopted by Special Resolution passed on 21 July 2017 and effective on 21 July 2017) THE COMPANIES LAW (2016 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF AS |
|
| March 6, 2019 |
CBPO / China Biologic Products, Inc. 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| March 6, 2019 |
Employment Agreement between the Company and Huaming He dated December 3, 2018 EXHIBIT 4.42 Employment Agreement This Employment Agreement (this “Agreement”), dated as of December 3, 2018, is entered into between China Biologic Products Holdings, Inc., a company established in the Cayman Islands with its principal office located at 18th Floor, Jialong Int’l Tower, 19 Chaoyang Park Road, Beijing 100125, PRC (“Company”), and Huaming He (the “Executive”). WHEREAS, the Company d |
|
| March 6, 2019 |
Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bing Li, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make th |
|
| March 6, 2019 |
EXHIBIT 11.1 CODE OF ETHICS OF CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. I. Objectives China Biologic Products Holdings, Inc. and its subsidiaries (together, the “Company”) is committed to the highest level of ethical behavior. The Company’s business success depends upon the reputation of the Company and its directors, officers and employees to perform with the highest level of integrity and principl |
|
| March 6, 2019 |
Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of China Biologic Products Holdings, Inc. (the “Company”) on Form 20-F for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ming Yang, Chief Financial Officer of the Compan |
|
| March 6, 2019 |
Consent of independent registered public accounting firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors China Biologic Products Holdings, Inc. We consent to the incorporation by reference in the Registration Statement (No. 333-151263) on Form S-8 (as amended by Post-Effective Amendment No. 1) of China Biologic Products Holdings, Inc. (the “Company”) of our reports dated March 6, 2019, with respect to the con |
|
| March 6, 2019 |
Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| February 20, 2019 |
CBPO / China Biologic Products, Inc. 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 2 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Exact name of Registrant as specified in its Charter) Cayman Islands 75-2308816 (State or other jurisdiction of incorporation or organizati |
|
| February 20, 2019 |
AMENDMENT NO. 1 TO AMENDED AND RESTATED PREFERRED SHARES RIGHTS AGREEMENT Exhibit 99.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED PREFERRED SHARES RIGHTS AGREEMENT AMENDMENT NO. 1 (this “Amendment”), dated as of February 20, 2019, to the Amended and Restated Preferred Shares Rights Agreement (the “Rights Agreement”), dated as of July 31, 2017, by and between China Biologic Products Holdings, Inc., a Cayman Islands company (the “Company”), and Securities Transfer Corporatio |
|
| February 20, 2019 |
CBPO / China Biologic Products, Inc. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoy |
|
| February 14, 2019 |
SC 13G/A 1 p19-0419sc13ga.htm CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) G21515104 (CUSIP Number) December 31, 2018 (Date of Event Whi |
|
| February 12, 2019 |
CBPO / China Biologic Products, Inc. / Parfield International Ltd Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURUSANT TO § 240.13d-2 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) G21515104 (CUSIP Number) December 31, 201 |
|
| February 4, 2019 |
CBPO / China Biologic Products, Inc. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number 001-34566 China Biologic Products Holdings, Inc. (Exact name of registrant as specified in its charter) 18th Floor, Jialong International Building, 19 Chaoy |
|
| February 4, 2019 |
SC 13D/A 1 dp101925sc13da-a4.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* China Biologic Products Holdings, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.0001 (Title of Class of Securities) G21515104 (CUSIP Number) Andrew Chan Chief Financial Officer Centurium Capital Manage |
